Physician profile
Amy J Tseng
NPI 1497844104
$4,171.25
in general payments reported to CMS, 2019-2025
15 companies · $795 in 2025
The $795 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $479 · 2021: $380 · 2022: $827 · 2023: $394 · 2024: $600 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,422.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,129.54 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $517.41 | 2022-2023 | Skyrizi |
| Merz North America, INC. | $322.32 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $159.03 | 2019 | |
| Lilly USA, LLC | $147.23 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.41 | 2021-2025 | Jardiance |
| Pfizer INC. | $127.84 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.07 | 2025 | |
| Astellas Pharma US INC | $18.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.41 | 2019 | |
| Amarin Pharma, INC. | $14.83 | 2021 | |
| Abbott Laboratories | $13.98 | 2021 | |
| Dexcom, INC. | $12.63 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Tseng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.